Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 Combined With TACE for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07398664Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Oncorine in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started Mar 2026; status: recruiting.
02
Drugs
Oncorine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07398664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398664.